scholarly journals Immunogenicity and adverse events of priming with inactivated whole SARS-CoV-2 vaccine (CoronaVac) followed by boosting the ChAdOx1 nCoV-19 vaccine

2021 ◽  
Author(s):  
Surakameth Mahasirimongkol ◽  
Athiwat Khunphon ◽  
Oraya Kwangsukstid ◽  
Sompong Sapsutthipas ◽  
Minkwan Wichaidit ◽  
...  
Keyword(s):  
Adverse Events ◽  
Virus Vaccine ◽  
Viral Vector ◽  
Natural Infection ◽  
Geometric Mean ◽  
Wild Type ◽  
Vaccine Regimen ◽  
Vector Vaccine ◽  
Boost Vaccine ◽  
Viral Vector Vaccine

Background: Responding to SARS-CoV-2 Delta variants escaped the vaccine-induced immunity and waning immunity from the inactivated whole virus vaccine, Thailand recently proposed a heterologous inactivated whole virus vaccine (CoronaVac) viral vector vaccine (ChAdOx1 nCoV-19) prime-boost vaccine regimen(I/V). This study aims to evaluate the immunogenicity and adverse events of this regimen by comparison with homologous CoronaVac, ChAdOx1 nCoV-19, and convalescent serum. Method: Immunogenicity was evaluated by the level of IgG antibodies against the receptor-binding domain of the SARS-CoV-2 spike protein (S1 subunit) (anti-S RBD). At 2 weeks following the second dosage, a selection of random samples was tested for plaque reduction neutralisation (PRNT) and Pseudotype-Based Microneutralization test (PVNT) against SARS-CoV-2 variants of concern (VOCs). The safety profile of heterologous CoronaVac-ChAdOx1 nCoV-19 prime-boost vaccine regimen was described by interviewing at the 1-month visit. Result: Between April to August 2021,426 participants were included in the study, with 155 obtaining CoronaVac-ChAdOx1 nCoV-19(I/V),32 obtaining homologous CoronaVac(I/I),47 obtaining homologous ChAdOx1 nCoV-19(V/V),169 with history covid-19 infection. Geometric mean titers (GMTs) of anti-S RBD level in the I/V group compare 2wks and 4 wks ( 873.9 vs 639,p=0.00114).At 4 wks, GMTs of anti-S RBD level in I/V group was 639, 95% CI 63-726,and natural infection group 177.3, 95% CI 42-221, and V/V group 211.1, 95% CI 77-152 ,and I/I group 108.2 ,95% CI 77-152 ; all p<0.001).At 2 wks, The GMTs of 50%PRNT of 19 sampling from the I/V group is 434.5, 95% CI 326-579, against wild type and 80.4, 95% CI 56-115, against alpha and 67.4, 95% CI 48-95, against delta and 19.8, 95% CI 14-30, against beta; all p<0.001. At 2 wks, The GMTs of 50%PVNT of 15 sampling from the I/V group is 597.8, 95% CI 368-970, against wild type and 163.9, 95% CI 89-301, against alpha and 157.7, 95% CI 66-378, against delta. The AEs in the I/V schedule were well tolerated and generally unremarkable. Conclusion: The I/V vaccination is a mixed regimen that induced higher immunogenicity and shall be considered for responding to Delta Variants when only inactivated whole virus vaccine and viral vector vaccine was available.

Hatchery Vaccination Quality Control of Herpesvirus of Turkey-Infectious Bursal Disease HVT-IBD Viral Vector Vaccine Application by Specific qPCR

2012 ◽  
Vol 11 (9) ◽  
pp. 570-576 ◽  
Author(s):  
Stephane Lemiere ◽  
Francisco Perozo ◽  
Blandine de Saint-Vis ◽  
Jennifer Diasparra ◽  
Arnaud Carlotti ◽  
...  
Keyword(s):  
Quality Control ◽  
Viral Vector ◽  
Infectious Bursal Disease ◽  
Vector Vaccine ◽  
Bursal Disease ◽  
Viral Vector Vaccine

scholarly journals Developmental Landscape of Potential Vaccine Candidates Based on Viral Vector for Prophylaxis of COVID-19

2021 ◽  
Vol 8 ◽  
Author(s):  
Rajashri Bezbaruah ◽  
Pobitra Borah ◽  
Bibhuti Bhushan Kakoti ◽  
Nizar A. Al-Shar’I ◽  
Balakumar Chandrasekaran ◽  
...  
Keyword(s):  
Viral Vectors ◽  
Ebola Virus ◽  
Vaccine Development ◽  
Viral Vector ◽  
World Health ◽  
Prolonged Incubation ◽  
Vaccine Candidates ◽  
Vector Vaccine ◽  
Dna And Rna ◽  
Viral Vector Vaccine

Severe acute respiratory syndrome coronavirus 2, SARS-CoV-2, arose at the end of 2019 as a zoonotic virus, which is the causative agent of the novel coronavirus outbreak COVID-19. Without any clear indications of abatement, the disease has become a major healthcare threat across the globe, owing to prolonged incubation period, high prevalence, and absence of existing drugs or vaccines. Development of COVID-19 vaccine is being considered as the most efficient strategy to curtail the ongoing pandemic. Following publication of genetic sequence of SARS-CoV-2, globally extensive research and development work has been in progress to develop a vaccine against the disease. The use of genetic engineering, recombinant technologies, and other computational tools has led to the expansion of several promising vaccine candidates. The range of technology platforms being evaluated, including virus-like particles, peptides, nucleic acid (DNA and RNA), recombinant proteins, inactivated virus, live attenuated viruses, and viral vectors (replicating and non-replicating) approaches, are striking features of the vaccine development strategies. Viral vectors, the next-generation vaccine platforms, provide a convenient method for delivering vaccine antigens into the host cell to induce antigenic proteins which can be tailored to arouse an assortment of immune responses, as evident from the success of smallpox vaccine and Ervebo vaccine against Ebola virus. As per the World Health Organization, till January 22, 2021, 14 viral vector vaccine candidates are under clinical development including 10 nonreplicating and four replicating types. Moreover, another 39 candidates based on viral vector platform are under preclinical evaluation. This review will outline the current developmental landscape and discuss issues that remain critical to the success or failure of viral vector vaccine candidates against COVID-19.

Evaluation of the protective effect of a prime-boost strategy with plasmid DNA followed by recombinant adenovirus expressing BmAMA1 as vaccines against Babesia microti infection in hamster

2018 ◽  
Vol 63 (2) ◽  
pp. 368-374
Author(s):  
Guanbo Wang ◽  
Longzheng Yu ◽  
Artemis Efstratiou ◽  
Paul Franck Adjou Moumouni ◽  
Mingming Liu ◽  
...  
Keyword(s):  
Protective Effect ◽  
Plasmid Dna ◽  
Viral Vector ◽  
Recombinant Adenovirus ◽  
Vaccination Strategy ◽  
Challenge Infection ◽  
Babesia Microti ◽  
Post Challenge ◽  
Vector Vaccine ◽  
Viral Vector Vaccine

AbstractIn the present study, we have investigated the protective effect of a heterologous prime-boost strategy with priming plasmid DNA followed by recombinant adenovirus, both expressing BmAMA1, againstBabesia microtiinfection. Four groups consisting of 3 hamsters per group were immunized with pBmAMA1/Ad5BmAMA1, pNull/Ad5BmAMA1, pBmAMA1/Ad5Null and pNull/Ad5Null, followed by challenge infection withB.microti. Our results showed that hamsters immunized with plasmid and adenovirus expressing BmAMA1 developed a robust IgG and IgG2a antibody response against BmAMA1, suggesting the DNA vaccine or viral vector vaccine tend to induce a Th1-biased response. Compared to the control hamsters, the hamsters vaccinated either with the prime-boost strategy or one of the two “vaccines” exhibited no significant protection againstB.microtichallenge. Although a slight difference in terms of parasitemia and hematocrit values at days 14–16 post challenge infection was observed, no other statistical difference was detected. Our results indicate that the prime-boost vaccination strategy of injection of plasmid and adenovirus expressing BmAMA1 is not efficient in protecting againstB.microtiinfection.

scholarly journals SARS-CoV-2 Vaccine-Induced Antibody Response and Reinfection in Persons with Past Natural Infection

2021 ◽  
Author(s):  
Nitu Chauhan ◽  
Ajeet Singh Chahar ◽  
Prem Singh ◽  
Neel Sarovar Bhavesh ◽  
Ravi Tandon ◽  
...  
Keyword(s):  
Viral Vector ◽  
Natural Infection ◽  
Previous History ◽  
Adenovirus Vector ◽  
Prior History ◽  
Igg Antibody ◽  
Vector Vaccine ◽  
Women Subjects ◽  
History Of ◽  
Antibody Titers

Several studies have shown that subjects with a history of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection had significantly higher antibody titers than previously uninfected vaccinees after vaccination with mRNA vaccine. Yet no information is available for other vaccines. In the current observational cohort study, 105 health care workers who had received Covishield an Adeno associated viral vector-based DNA vaccine were enrolled at Sarojini Nadu Medical College Agra, India. The study included 40 (23 men and 17 women) subjects with a previous history of SARS-CoV-2 infection and 65 participants (39 men and 26 women) who were not infected previously. Both the groups received the adenovirus vector vaccine ChAdOx1-S recombinant vaccines (Covishield, Astra Zeneca). The levels of SARS-CoV-2-anti-spike-IgG-antibodies titer were measured using Electrochemiluminescence immunoassay on Roche platform as arbitrary units per milliliter (AU/ml). After 28 days of the second dose, subjects with no previous SARSCoV-2 infection showed a significantly lower level of circulating anti-spike-IgG-antibody titers compared to previously infected participants. After the second dose, we also observed a significant increase in SARS-CoV-2 infection in subjects with no prior history of SARS-CoV-2 infection compared to subjects with a previous history of natural infection. The most important observation of the study is a low percentage of infection in previously infected subjects. The finding of the study also indicates the presence of robust humoral memory response in previously infected patients.

scholarly journals Safety of the novel influenza viral vector Brucella abortus vaccine in pregnant heifers

2015 ◽  
Vol 46 (1) ◽  
pp. 114-118 ◽  
Author(s):  
Kaissar Tabynov ◽  
Sholpan Ryskeldinova ◽  
Zhailaubay Kydyrbayev ◽  
Abylai Sansyzbay
Keyword(s):  
Brucella Abortus ◽  
Viral Vector ◽  
Booster Vaccination ◽  
Positive Control ◽  
Control Group ◽  
The Novel ◽  
Subcutaneous Route ◽  
Control Groups ◽  
Vector Vaccine ◽  
Viral Vector Vaccine

ABSTRACT: The present study provides the first information about the safety of a new influenza viral vector vaccine expressing the Brucella ribosomal protein L7/L12 or Omp16 containing the adjuvant Montanide Gel01 in pregnant heifers. Immunization of pregnant heifers was conducted via the conjunctival (n=10) or subcutaneous (n=10) route using cross prime and booster vaccination schedules at an interval of 28 days. The vector vaccine was evaluated in comparison with positive control groups vaccinated with B. abortus S19 (n=10) or B. abortus RB51 (n=10) and a negative (PBS+Montanide Gel01; n=10) control group. Clinical studies, thermometry, assessment of local reactogenicity and observation of abortion showed that the vector vaccine via the conjunctival or subcutaneous route was completely safe for pregnant heifers compared to the commercial vaccines B. abortus S19 or B. abortus RB51. The only single adverse event was the formation of infiltration at the site of subcutaneous injection; this reaction was not observed for the conjunctival route.

scholarly journals Cutting Edge: Mucosal Application of a Lyophilized Viral Vector Vaccine Confers Systemic and Protective Immunity toward Intracellular Pathogens

2009 ◽  
Vol 182 (5) ◽  
pp. 2573-2577 ◽  
Author(s):  
Wolfgang Kastenmuller ◽  
Georg Gasteiger ◽  
Leon Stross ◽  
Dirk H. Busch ◽  
Ingo Drexler
Keyword(s):  
Protective Immunity ◽  
Viral Vector ◽  
Cutting Edge ◽  
Intracellular Pathogens ◽  
Vector Vaccine ◽  
Viral Vector Vaccine

Bilateral Immune-Mediated Keratolysis After Immunization With SARS-CoV-2 Recombinant Viral Vector Vaccine

Cornea ◽  
2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Tanveer Alam Khan ◽  
Navneet Sidhu ◽  
Livia Khan ◽  
Seema Sen ◽  
Nishat Hussain ◽  
...  
Keyword(s):  
Viral Vector ◽  
Vector Vaccine ◽  
Immune Mediated ◽  
Viral Vector Vaccine

scholarly journals Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine

2021 ◽  
Author(s):  
Sitthichai Kanokudom ◽  
Suvichada Assawakosri ◽  
Nungruthai Suntronwong ◽  
Chompoonut Auphimai ◽  
Pornjarim Nilyanimit ◽  
...  
Keyword(s):  
Adverse Events ◽  
Booster Dose ◽  
Viral Vector ◽  
Significant Proportion ◽  
Booster Vaccination ◽  
T Cell Response ◽  
Healthy Adults ◽  
Inactivated Vaccine ◽  
Serious Adverse Events ◽  
Vector Vaccine

AbstractThe coronavirus disease-2019 (COVID-19) pandemic has become a severe healthcare problem worldwide since the first outbreak in late December 2019. Currently, the COVID-19 vaccine has been used in many countries, but it is still unable to control the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection despite patients receiving full vaccination doses. Therefore, we aimed to appraise the booster effect of the different platforms of vaccines, including inactivated vaccine (BBIBP), viral vector vaccine (AZD122), and mRNA vaccine (BNT162b2) in healthy adults who received the full dose of inactivated vaccine (CoronaVac). The booster dose was safe with no serious adverse events. Moreover, the immunogenicity indicated that the booster dose with viral vector and mRNA vaccine achieved a significant proportion of Ig anti-receptor binding domain (RBD), IgG anti-RBD, and IgA anti-S1 booster response. In contrast, inactivated vaccine achieved a lower booster response than others. Consequently, the neutralization activity of vaccinated serum had a high inhibition of over 90% against SARS-CoV-2 wild-type and their variants (B.1.1.7–alpha, B.1.351–beta, and B.1.617.2–delta). In addition, IgG anti-nucleocapsid was observed only among the group that received the BBIBP booster. Our study found a significant increase in levels of interferon gamma-secreting T-cell response after the additional viral vector or mRNA booster vaccination. This study showed that administration with either viral vector (AZD1222) or mRNA (BNT162b2) boosters in individuals with a history of two doses of inactivated vaccine (CoronaVac) obtained great immunogenicity with acceptable adverse events.

Sign in / Sign up

Export Citation Format

Share Document